{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:12:48Z","timestamp":1788469968471,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370096"],"award-info":[{"award-number":["82370096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172728"],"award-info":[{"award-number":["82172728"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Innovation Research Project of Jinling Hospital","award":["2023JCYJZD080"],"award-info":[{"award-number":["2023JCYJZD080"]}]},{"name":"Science and Technology Innovation Research Project of Jinling Hospital","award":["22LCYY-LH3"],"award-info":[{"award-number":["22LCYY-LH3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04057-y","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:51:55Z","timestamp":1761663115000},"page":"1246-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intrapleural anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer with malignant pleural effusion: a prospective, single-arm, single-center, phase I trial"],"prefix":"10.1007","volume":"28","author":[{"given":"Yuting","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinpei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xincui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangfeng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3030-2662","authenticated-orcid":false,"given":"Ping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"3","key":"4057_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.mcna.2018.12.007","volume":"103","author":"M Aboudara","year":"2019","unstructured":"Aboudara M, Maldonado F. Update in the management of pleural effusions. Med Clin N Am. 2019;103(3):475\u201385. https:\/\/doi.org\/10.1016\/j.mcna.2018.12.007.","journal-title":"Med Clin N Am"},{"key":"4057_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106802","volume":"196","author":"SI Bashour","year":"2022","unstructured":"Bashour SI, Mankidy BJ, Lazarus DR. Update on the diagnosis and management of malignant pleural effusions. Respir Med. 2022;196:106802. https:\/\/doi.org\/10.1016\/j.rmed.2022.106802.","journal-title":"Respir Med"},{"issue":"2","key":"4057_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.21037\/jtd.2019.01.36","volume":"11","author":"O Arrieta","year":"2019","unstructured":"Arrieta O, Escamilla-L\u00f3pez I, Lyra-Gonz\u00e1lez I, et al. Radical aggressive treatment among non-small cell lung cancer patients with malignant pleural effusion without extra-thoracic disease. J Thorac Dis. 2019;11(2):595\u2013601. https:\/\/doi.org\/10.21037\/jtd.2019.01.36.","journal-title":"J Thorac Dis"},{"key":"4057_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1186\/s12885-018-4581-5","volume":"18","author":"L Han","year":"2018","unstructured":"Han L, Jiang Q, Yao W, Fu T, Zeng Q. Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients. BMC Cancer. 2018;18:725. https:\/\/doi.org\/10.1186\/s12885-018-4581-5.","journal-title":"BMC Cancer"},{"issue":"1","key":"4057_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/ejcts\/ezy258","volume":"55","author":"AC Bibby","year":"2019","unstructured":"Bibby AC, Dorn P, Psallidas I, et al. ERS\/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg. 2019;55(1):116\u201332. https:\/\/doi.org\/10.1093\/ejcts\/ezy258.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"10","key":"4057_CR6","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.amjmed.2022.04.017","volume":"135","author":"S Gayen","year":"2022","unstructured":"Gayen S. Malignant pleural effusion: presentation, diagnosis, and management. Am J Med. 2022;135(10):1188\u201392. https:\/\/doi.org\/10.1016\/j.amjmed.2022.04.017.","journal-title":"Am J Med"},{"issue":"8","key":"4057_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/medicina55080490","volume":"55","author":"K Skok","year":"2019","unstructured":"Skok K, Hladnik G, Grm A, Crnjac A. Malignant pleural effusion and its current management: a review. Medicina. 2019;55(8):490. https:\/\/doi.org\/10.3390\/medicina55080490.","journal-title":"Medicina"},{"issue":"19","key":"4057_CR8","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2017.17426","volume":"318","author":"R Thomas","year":"2017","unstructured":"Thomas R, Fysh ETH, Smith NA, et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA. 2017;318(19):1903. https:\/\/doi.org\/10.1001\/jama.2017.17426.","journal-title":"JAMA"},{"issue":"1","key":"4057_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jama.2019.19997","volume":"323","author":"R Bhatnagar","year":"2020","unstructured":"Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M, et al. Effect of thoracoscopic talc poudrage vs talc slurry via chest tube on pleurodesis failure rate among patients with malignant pleural effusions: a randomized clinical trial. JAMA. 2020;323(1):60. https:\/\/doi.org\/10.1001\/jama.2019.19997.","journal-title":"JAMA"},{"issue":"1","key":"4057_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","volume":"25","author":"F Gonnelli","year":"2024","unstructured":"Gonnelli F, Hassan W, Bonifazi M, et al. Malignant pleural effusion: current understanding and therapeutic approach. Respir Res. 2024;25(1):47. https:\/\/doi.org\/10.1186\/s12931-024-02684-7.","journal-title":"Respir Res"},{"issue":"4","key":"4057_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/MCP.0000000000000573","volume":"25","author":"CR Gilbert","year":"2019","unstructured":"Gilbert CR, Haouzi P. Particle size, distribution, and behavior of talc preparations: within the United States and beyond. Curr Opin Pulm Med. 2019;25(4):374. https:\/\/doi.org\/10.1097\/MCP.0000000000000573.","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"4057_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","volume":"198","author":"DJ Feller-Kopman","year":"2018","unstructured":"Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198(7):839\u201349. https:\/\/doi.org\/10.1164\/rccm.201807-1415ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7689","key":"4057_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354. https:\/\/doi.org\/10.1038\/nature25183.","journal-title":"Nature"},{"issue":"8","key":"4057_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356. https:\/\/doi.org\/10.1038\/s41591-021-01450-2.","journal-title":"Nat Med"},{"issue":"1","key":"4057_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-022-00363-7","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, Lin W, Tan F, et al. Sintilimab for the treatment of non-small cell lung cancer. Biomark Res. 2022;10(1):23. https:\/\/doi.org\/10.1186\/s40364-022-00363-7.","journal-title":"Biomark Res"},{"issue":"1","key":"4057_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102206","volume":"9","author":"C Chen","year":"2024","unstructured":"Chen C, Li Z, Xiong X, et al. Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial. ESMO Open. 2024;9(1):102206. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102206.","journal-title":"ESMO Open"},{"issue":"4","key":"4057_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1554969","volume":"8","author":"P Murthy","year":"2019","unstructured":"Murthy P, Ekeke CN, Russell KL, et al. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 2019;8(4):e1554969. https:\/\/doi.org\/10.1080\/2162402X.2018.1554969.","journal-title":"Oncoimmunology"},{"key":"4057_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.760683","volume":"12","author":"X Li","year":"2021","unstructured":"Li X, Wu G, Chen C, et al. Intrapleural injection of anti-PD1 antibody: a novel management of malignant pleural effusion. Front Immunol. 2021;12:760683. https:\/\/doi.org\/10.3389\/fimmu.2021.760683.","journal-title":"Front Immunol"},{"issue":"14","key":"4057_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1716883","volume":"378","author":"R Bhatnagar","year":"2018","unstructured":"Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med. 2018;378(14):1313\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1716883.","journal-title":"N Engl J Med"},{"issue":"1","key":"4057_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4057_CR21","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.7314\/APJCP.2013.14.4.2611","volume":"14","author":"XE Huang","year":"2013","unstructured":"Huang XE, Wei GL, Huo JG, et al. Intrapleural or intraperitoneal Lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev. 2013;14(4):2611\u20134. https:\/\/doi.org\/10.7314\/APJCP.2013.14.4.2611.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"4057_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/17476348.2018.1417042","volume":"12","author":"RL Sabang","year":"2018","unstructured":"Sabang RL, Gandhiraj D, Fanucchi M, Epelbaum O. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev Respir Med. 2018;12(2):87\u201394. https:\/\/doi.org\/10.1080\/17476348.2018.1417042.","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"4057_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3892\/ijo.2021.5174","volume":"58","author":"D He","year":"2021","unstructured":"He D, Ding R, Wen Q, Chen L. Novel therapies for malignant pleural effusion: anti-angiogenic therapy and immunotherapy (review). Int J Oncol. 2021;58(3):359\u201370. https:\/\/doi.org\/10.3892\/ijo.2021.5174.","journal-title":"Int J Oncol"},{"issue":"28","key":"4057_CR24","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. JCO. 2019;37(28):2518\u201327. https:\/\/doi.org\/10.1200\/JCO.19.00934.","journal-title":"JCO"},{"issue":"21","key":"4057_CR25","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%. JCO. 2021;39(21):2339\u201349. https:\/\/doi.org\/10.1200\/JCO.21.00174.","journal-title":"JCO"},{"issue":"3","key":"4057_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.4103\/jcrt.jcrt_739_22","volume":"20","author":"I Tsimafeyeu","year":"2024","unstructured":"Tsimafeyeu I, Goutnik V, Shrainer I, Kosyrev V, Bondarenko A, Utyashev I. Intrapleural nivolumab in cancer patients with pleural effusion. J Cancer Res Ther. 2024;20(3):1036\u20138. https:\/\/doi.org\/10.4103\/jcrt.jcrt_739_22.","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"4057_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12935-024-03211-w","volume":"24","author":"S Ge","year":"2024","unstructured":"Ge S, Zhao Y, Liang J, et al. Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications. Cancer Cell Int. 2024;24(1):105. https:\/\/doi.org\/10.1186\/s12935-024-03211-w.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"4057_CR28","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1055\/s-0043-1769094","volume":"44","author":"A Agrawal","year":"2023","unstructured":"Agrawal A, Chaddha U, Shojaee S, Maldonado F. Intrapleural anticancer therapy for malignant pleural diseases: facts or fiction? Semin Respir Crit Care Med. 2023;44(4):462\u20137. https:\/\/doi.org\/10.1055\/s-0043-1769094.","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"4057_CR29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/crj.13010","volume":"13","author":"V Murthy","year":"2019","unstructured":"Murthy V, Katzman D, Sterman DH. Intrapleural immunotherapy: an update on emerging treatment strategies for pleural malignancy. Clin Respir J. 2019;13(5):272\u20139. https:\/\/doi.org\/10.1111\/crj.13010.","journal-title":"Clin Respir J"},{"issue":"7","key":"4057_CR30","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008\u201319. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393.","journal-title":"JAMA Oncol"},{"issue":"8","key":"4057_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007441","volume":"11","author":"S Zhang","year":"2023","unstructured":"Zhang S, Peng W, Wang H, et al. C1q + tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion. J Immunother Cancer. 2023;11(8):e007441. https:\/\/doi.org\/10.1136\/jitc-2023-007441.","journal-title":"J Immunother Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04057-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:06:13Z","timestamp":1774415173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04057-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4057"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04057-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the affiliation for authors Tangfeng Lv and Ping Zhan. In-text reference citation for Reference 11 is included.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflicts of interest. The abstract of this research has been accepted as written communication for the 2024 Annual Respiratory Medicine Conference organized by the Chinese Medical Association (CMA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval Study protocol was approved by the Ethical Committee and Institutional Review Board of Jinling Hospital, the Affiliated Hospital of the Medical School at Nanjing University (Ethical Code: 2018NZKY-031-03). Acknowledgements We are thankful to all the research staff and co-investigators involved in this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}